UniQure AMT-130 Leading the Way for More Gene Silencing Drugs

By Dr Rachel Harding & Dr Sarah Hernandez
June 17, 2026

The Other Shoe Drops: uniQure Shares Plans To Submit Licensing Application With The FDA for AMT-130

The Other Shoe Drops: uniQure Shares Plans To Submit Licensing Application With The FDA for AMT-130

“After a turbulent past year, uniQure have shared encouraging news that the FDA has agreed their Phase I/II study data can serve as the basis for an application that could lead to the approval of AMT-130 in the US.”

Read the full article: https://en.hdbuzz.net/the-other-shoe-drops-uniqure-shares-plans-to-submit-licensing-application-with-the-fda-for-amt-130/

By Dr Rachel Harding & Dr Sarah Hernandez
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease

 

Bi-Monthly Advocacy Newsletter: Visit HDSA.org/Takeaction to read the New Bi-Monthly Advocacy Newsletter for updates.